SBIR-STTR Award

The proposed effort comprises a treatment combination using the platelet binding hemostatic capability of Nanoscopic Chemicals known as POSS trisilanols in combination with hyaluronic acid media, and antibiotic drugs in liquid and foam form. Mechanistically, liquid POSS trisilanols are injectable and serve to bind platelets to immediately stop bleeding. Subsequently the bound plateles release a multitude of natural growth factors while in the presence of a supplement of Hyaluronic acid (HA). Growth factors in combination with high amounts of HA are known to aid tissue repair and preservation.

Keywords:
Tissue, Tissue, Platelets, Hemostat, Hyaluronic Acid, Poss, Wound Healing

The proposed effort aims to increase the TRL of the hemostatic agent through completion of relevant animal and toxicological research and development. These advancements will be verified through process improvements to meet good manufacturing practices. A series of registration approvals for the device along with packaging requirements will be advanced. Additional efficacy and competitive performance metrics for the device will be developed and utilized to achieve FDA and DoD approvals.